BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 205 filers reported holding BRIDGEBIO PHARMA INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,735,933 | +53.3% | 331,283 | 0.0% | 0.68% | +17.8% |
| Q2 2023 | $5,698,068 | +3.7% | 331,283 | 0.0% | 0.57% | +12.1% |
| Q1 2023 | $5,492,672 | +117.6% | 331,283 | 0.0% | 0.51% | +99.6% |
| Q4 2022 | $2,524,376 | -23.3% | 331,283 | 0.0% | 0.26% | +21.9% |
| Q3 2022 | $3,293,000 | +9.5% | 331,283 | 0.0% | 0.21% | +3.4% |
| Q2 2022 | $3,008,000 | -10.6% | 331,283 | 0.0% | 0.20% | +6.8% |
| Q1 2022 | $3,363,000 | -39.1% | 331,283 | 0.0% | 0.19% | -45.2% |
| Q4 2021 | $5,526,000 | -64.4% | 331,283 | 0.0% | 0.35% | -70.0% |
| Q3 2021 | $15,527,000 | -23.1% | 331,283 | 0.0% | 1.16% | -38.7% |
| Q2 2021 | $20,195,000 | -1.0% | 331,283 | 0.0% | 1.89% | +4.5% |
| Q1 2021 | $20,407,000 | – | 331,283 | – | 1.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |